{"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"groups":[{"description":"Experimental: Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging\n\nIn this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys.","id":"BG000","title":"All Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"63","upperLimit":"76","value":"72"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6","upperLimit":"9","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Time Since SA Diagnosis","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.9","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time Since baseline imaging in AMY1001 study (years)","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"AL Kappa"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"AL Lambda"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"ATTR; Mutation type L58H"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"ATTR; Mutation type T60A"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"ATTR; Mutation type V30M and V122I"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"ATTR; Mutation type Wild type"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Amyloid Type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"9"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"% of AL patients; n=9","title":"Amyloid therapy at time of imaging of AL","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Stabilizer only"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Silencer only"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Stabilizer and silencer"}],"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"% of ATTR patients; n=10, Abbreviations: AL = light chain-associated amyloidosis; ATTR = transthyretin-associated amyloidosis","title":"Amyloid therapy at time of imaging of ATTR","unitOfMeasure":"Participants"}]}